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A B S T R A C T
Purpose
This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined
with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior to that of FOLFOX-4 alone as
first-line treatment for metastatic colorectal cancer. The influence of KRAS mutation status
was investigated.
Patients and Methods
Patients received cetuximab (400 mg/m2 initial dose followed by 250 mg/m2/wk thereafter) plus
FOLFOX-4 (oxaliplatin 85 mg/m2 on day 1, plus leucovorin 200 mg/m2 and fluorouracil as a 400
mg/m2 bolus followed by a 600 mg/m2 infusion during 22 hours on days 1 and 2; n  169) or
FOLFOX-4 alone (n  168). Treatment was continued until disease progression or unacceptable
toxicity. KRAS mutation status was assessed in the subset of patients with assessable tumor
samples (n  233).
Results
The confirmed ORR for cetuximab plus FOLFOX-4 was higher than with FOLFOX-4 alone (46% v
36%). A statistically significant increase in the odds for a response with the addition of cetuximab
to FOLFOX-4 could not be established (odds ratio  1.52; P  .064). In patients with KRAS
wild-type tumors, the addition of cetuximab to FOLFOX-4 was associated with a clinically
significant increased chance of response (ORR  61% v 37%; odds ratio  2.54; P  .011) and
a lower risk of disease progression (hazard ratio  0.57; P  .0163) compared with FOLFOX-4
alone. Cetuximab plus FOLFOX-4 was generally well tolerated.
Conclusion
KRAS mutational status was shown to be a highly predictive selection criterion in relation to the
treatment decision regarding the addition of cetuximab to FOLFOX-4 for previously untreated
patients with metastatic colorectal cancer.
J Clin Oncol 27:663-671. © 2008 by American Society of Clinical Oncology
INTRODUCTION
The epidermal growth factor receptor (EGFR) is a
clinically validated anticancer molecular target that
is expressed in the majority of colorectal tumors.1-5
Cetuximab (Erbitux, developed by Merck KGaA
[Darmstadt, Germany], under license from Im-
clone New York, NY]) is an immunoglobulin
G1 monoclonal antibody that specifically targets
EGFR with high affinity, competitively inhibit-
ing endogenous ligand binding and ligand-
dependent downstream signaling.6,7 Binding to
the tumor cell also initiates antibody-dependent
cell-mediated cytotoxicity.8-10 Randomized phase
II and III metastatic colorectal cancer (mCRC)
studies have demonstrated the efficacy and toler-
ability of cetuximab, as monotherapy2,11 or in
combination with irinotecan,2,12 after the failure
of previous chemotherapy regimens including
irinotecan and/or oxaliplatin. Furthermore, in
the first-line setting, building on promising phase
II data,13 the phase III Cetuximab Combined
With Irinotecan in First-Line Therapy for Meta-
static Colorectal Cancer (CRYSTAL) study has
shown that the addition of cetuximab to infu-
sional fluorouracil (FU)/leucovorin (LV)/irino-
tecan (FOLFIRI) significantly improves the
progression-free survival (PFS) time, response rate,
and R0 resection rate in mCRC patients, compared
with FOLFIRI alone.14
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Phase II studies examining the activity and tolerability of cetux-
imab combined with oxaliplatin and FU/LV (FOLFOX-4) have pro-
vided encouraging results.15,16 To further evaluate this combination,
the Oxaliplatin and Cetuximab in First-Line Treatment of mCRC
(OPUS) study compared the efficacy and safety of cetuximab plus
FOLFOX-4 with FOLFOX-4 alone as first-line therapy for mCRC.
The definition of relevant molecular characteristics of an in-
dividual tumor (biomarker evaluation) will increasingly enable the
selection of patients most likely to benefit from particular treat-
ments.17 A recent subgroup analysis of a randomized phase III
study of the immunoglobulin G2 EGFR-targeting monoclonal an-
tibody panitumumab in patients with chemotherapy-refractory
mCRC suggested a lack of clinical activity in patients whose tumors
had activating mutations at codon 12 or 13 of the KRAS gene.18
Small retrospective studies in chemotherapy-refractory patients
have also suggested that clinical responses to cetuximab are con-
fined to those mCRC patients (approximately 55% to 70%) whose
tumors are wild type for KRAS.19-22 This assertion has recently
been confirmed in subgroup analyses of the randomized phase III
CRYSTAL and CO.17 studies.23,24 A subgroup analysis of the OPUS
study therefore investigated whether tumor KRAS mutation status
was predictive of a clinical response to cetuximab plus FOLFOX-4.
PATIENTS AND METHODS
Patient Eligibility
Patients were eligible for inclusion if they were 18 years old; had a
histologically confirmed, first-occurrence of a nonresectable, EGFR-
expressing mCRC with at least one radiologically measurable lesion; a life
expectancy of 12 weeks; an Eastern Cooperative Oncology Group Perfor-
mance Status (ECOG PS) 2; and adequate hepatic, renal, and bone marrow
function. Patients were ineligible if they were pregnant, had a history of
previous exposure to EGFR-targeted therapy or previous chemotherapy (ex-
cept adjuvant treatment) for mCRC, or had uncontrolled severe organ or
metabolic dysfunction. The study was approved by relevant ethics committees
and was conducted in accordance with the Declaration of Helsinki. All patients
provided written, informed consent.
Study Design
This was an open-label, randomized, multicenter phase II study compar-
ing the efficacy and safety of cetuximab combined with FOLFOX-4 versus
FOLFOX-4 alone in the first-line treatment of EGFR-expressing mCRC.
EGFR expression was determined using a DakoCytomation pharmDx immu-
nohistochemistry kit (Dako, Glostrup, Denmark), with one tumor cell stain-
ing to any intensity being the minimum criterion required to confirm
expression. Randomization (1:1) was carried out using a stratified permuted-
block procedure, with ECOG PS (0 and 1 v 2) as a stratification factor.
On day 1 of a 14-day treatment cycle, patients received cetuximab
(initial dose 400 mg/m2 infused during 2 hours, and 250 mg/m2 weekly
during 1 hour thereafter) followed after 1 hour by FOLFOX-4 (oxaliplatin
85 mg/m2 on day 1, infused during 2 hours; LV 200 mg/m2, infused during
2 hours, followed by FU as a 400 mg/m2 intravenous bolus then a 600
mg/m2 infusion during 22 hours on days 1 and 2) or FOLFOX-4 alone,
until the occurrence of progressive disease (PD) or unacceptable toxicity.
In the case of unacceptable toxicity or intolerance to FU/LV, oxaliplatin, or
cetuximab, the agent responsible could be stopped and the patient could
continue with the other study medication(s). Radiologic assessment of re-
sponse was carried out every 8 weeks until PD or withdrawal for any reason.
The primary objective was to assess whether the best confirmed
overall response rate of cetuximab plus FOLFOX-4 was superior to that of
FOLFOX-4 alone. Tumor response including disease progression was as-
sessed by an independent review committee according to modified WHO
criteria. The independent review committee conducted a blinded review of
images and clinical data using a common set of prespecified criteria. The
data cutoff for the primary analysis of response was chosen to be 20 weeks
after the last randomly assigned patient started study treatment (August 4,
2006) so that all patients could have at least two 8-week evaluations.
Secondary objectives included treatment comparisons of the rate of cura-
tive metastatic surgery, duration of response, disease control rate, PFS
time, OS time, and safety, all of which were based on data from a longer
follow-up time (March 1, 2007). A retrospective subgroup analysis inves-
tigated associations between PFS and response rate and the KRAS muta-
tion status of tumors.
Statistical Methods and Considerations
The primary efficacy analysis was performed on the intention-to-
treat (ITT) population, defined as all randomly assigned patients who
received at least one dose of study treatment. Assuming a difference in the
rate of best confirmed response of at least 20% between the two treatments
(ie, approximately 70% with cetuximab plus FOLFOX-4 and 50% with
FOLFOX-4 alone for the stratum with ECOG PS 0 to 1, and 66% and 45%,
respectively, for the ECOG PS 2 stratum), the Cochran-Mantel-Haenszel
(CMH)25,26 odds ratio (OR) over the strata was expected to be 2.33. A
sample size of approximately 146 patients per group was therefore calcu-
lated as necessary to detect an odds ratio of 2.33 at level   .05, with a
Screened at baseline
(n = 364)
Prescreened
(n = 629)
Screened for tumor EGFR expression
(n = 607)
Randomly assigned
(n = 341)
(plus 3 not eligible)
Randomly assigned
(n = 344)
Treated
(n = 338)
Cetuximab + FOLFOX-4
(n = 170)
(ITT population: n = 169) 
Main reason for end of treatment
  Progressive disease n = 87
  Stable disease n = 3
  Adverse event n = 12
  Death n = 9
  Noncompliance n = 7
  Withdrew consent n = 19
  Other n = 7
FOLFOX-4
(n = 168)
(ITT population: n = 168)
Main reason for end of treatment
  Progressive disease n = 92
  Stable disease n = 5
  Adverse event n = 26
  Death n = 5
  Noncompliance n = 5
  Withdrew consent n = 18
  Other n = 5
Not eligible
for study
(n = 23)
Not treated
(n = 6)
Not eligible
for baseline
screening
(n = 265)
Fig 1. Disposition of subjects at the time of the data cutoff March 1, 2007.
EGFR, epidermal growth factor receptor; FOLFOX-4, oxaliplatin, leucovorin, and
fluorouracil; ITT, intention to treat.
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power of 90%. With the exception of the test of the null hypothesis of
OR 1 over the entire sample population, all further efficacy analyses were
exploratory and P values were not adjusted for the multiplicity of statistical
tests. Time-to-event data were analyzed using the Kaplan-Meier method.27
All analyses were repeated by KRAS mutation status in those ITT patients
whose tumors were available and provided an assessable DNA sample
(KRAS population).
KRAS Mutation Detection
Tumor DNA was extracted from formaldehyde-fixed paraffin-embedded
tissues, and screened for the presence of KRAS codon 12 and 13 mutations
using a polymerase chain reaction (PCR) clamping and melting curve tech-
nique adapted from Chen et al28 (full methods information is listed in the
Appendix, online only). Briefly, a one-step Lightcycler PCR reaction (Light-
Mix, k-ras Gly12; TIB MOLBIOL, Berlin, Germany) incorporated a codon 12
Table 1. Patient and Disease Characteristics at Baseline
Characteristic
ITT Population (n  337) KRAS Population (n  233) KRAS Wild Type (n  134) KRAS Mutant (n  99)
FOLFOX-4
(n  168)
Cetuximab 
FOLFOX-4
(n  169)
FOLFOX-4
(n  120)
Cetuximab 
FOLFOX-4
(n  113)
FOLFOX-4
(n  73)
Cetuximab 
FOLFOX-4
(n  61)
FOLFOX-4
(n  47)
Cetuximab 
FOLFOX-4
(n  52)
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
Sex
Male 92 55 89 53 66 55 57 50 44 60 30 49 22 47 27 52
Female 76 45 80 47 54 45 56 50 29 40 31 51 25 53 25 48
Age, years
Median 60 62 60 59 59 59 61 60
Range 30-82 24-82 30-82 24-82 36-82 24-74 30-75 41-82
 65 109 65 96 57 77 64 70 62 46 63 39 64 31 66 31 60
 65 59 35 73 43 43 63 43 38 27 37 22 36 16 34 21 40
Region
Eastern Europe 93 55 97 57 71 59 70 62 45 62 38 62 26 55 32 62
Western Europe 49 29 45 27 49 41 43 38 28 38 23 38 21 45 20 38
Southern Europe 25 15 27 16 0 0 0 0 0 0
ROW 1 1 0 0 0 0 0 0 0
ECOG PS at baseline
0 75 45 65 39 50 42 34 30 27 37 19 31 23 49 15 29
1 76 45 89 53 56 47 70 62 37 51 37 61 19 40 33 63
2 17 10 15 9 14 12 9 8 9 12 5 8 5 11 4 8
Disease duration, months
Median, CRC 2.2 2.1 2.1 2.2 2.0 2.1 2.1 2.3
Q1-Q3 1.3-17.6 1.2-9.8 1.3-14.4 1.4-10.7 1.3-15.0 1.2-9.4 1.2-7.8 1.6-10.7
Median, mCRC 1.5 1.4 1.6 1.4 1.6 1.3 1.4 1.6
Q1-Q3 1.1-2.3 0.9-2.3 1.1-2.3 1.0-2.4 1.2-2.2 0.9-2.4 1.1-2.3 1.0-2.4
Tumor site
Colon 89 53 92 54 66 55 61 54 41 56 31 51 25 53 30 58
Rectum 79 47 75 44 54 45 51 45 32 44 30 49 22 47 21 40
Colon  rectum 0 2 1 0 1 1 0 0 0 1 2
Metastatic sites
Liver 146 87 149 88 108 90 101 89 65 89 54 89 43 91 47 90
Lung 65 39 64 38 44 37 45 40 27 37 16 26 17 36 29 56
Bone 4 2 9 5 3 3 4 4 3 4 1 2 0 3 6
Lymph node 45 27 41 24 32 27 25 22 19 26 15 25 13 28 10 19
Other 27 16 25 15 17 14 17 15 12 16 9 15 5 11 8 15
Organs with metastases
0 1 0.6 0 0 0 0 0 0 0
1 69 41 74 44 52 43 50 44 31 42 32 52 21 45 18 35
2 63 38 60 36 41 34 38 34 24 33 17 28 17 36 21 40
3 18 11 22 13 15 13 16 14 12 16 9 15 3 6 7 13
 4 17 10 13 8 12 10 9 8 6 8 3 5 6 13 6 12
Prior therapy†
Surgery 152 91 137 81 108 90 100 88 67 92 50 82 41 87 50 96
Adjuvant chemotherapy 36 21 21 12 19 16 14 12 12 16 8 13 7 15 6 12
Radiotherapy 23 14 18 11 13 11 13 12 9 12 5 8 4 9 8 15
Abbreviations: ITT, intention to treat; FOLFOX-4, oxaliplatin, leucovorin, and fluorouracil; ROW, rest of the world; ECOG PS, Eastern Cooperative Oncology Group
performance status; CRC, colorectal cancer; mCRC, metastatic colorectal cancer; Q1-Q3, interquartile range.
Patient enrolled in violation of protocol.
†A patient may have received more than one prior therapy.
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to 14 spanning locked nucleic acid oligomer to suppress amplification of the
wild-type sequence.29 Post-PCR hybridization and melting curve analysis
using fluorescently tagged oligonucleotides incorporated in the original PCR
reaction permitted the identification and discrimination of distinct KRAS
codon 12 and 13 missense mutations.
Safety Analysis
The safety population comprised all patients who received at least one
dose of study treatment. All adverse events (AEs) reported with onset on or
after the first day of study medication and captured up to 6 weeks after the end
of the last administration of study treatment were coded using the Medical
Dictionary for Regulatory Activities version 8.1 and summarized by worst
severity per patient according to the National Cancer Institute Common
Toxicity Criteria version 2.0.
RESULTS
Patient Demographics
Three hundred forty-four patients were randomly assigned
(three of them in error). Of the eligible patients, 337 received study
treatment at 79 centers. Study accrual lasted from July 2005 until
March 2006, with 169 patients receiving cetuximab plus FOLFOX-4
and 168 patients receiving FOLFOX-4 alone (Fig 1). Baseline demo-
graphic and disease characteristics were generally well balanced be-
tween the treatment groups (Table 1). DNA suitable for KRAS
mutation analysis was extracted from the tumor samples of 233
patients, 113 and 120 of whom had received cetuximab plus
FOLOFOX-4 and FOLFOX-4 alone, respectively. These patients com-
prised the KRAS population. In general, the population with tissue
available for KRAS analysis (n 233) was considered to be represen-
tative of the overall ITT population (n  337) in relation to demo-
graphic parameters (Table 1).
Treatment Compliance
The median duration of cetuximab treatment was 24 weeks, with
84% of patients having a relative dose-intensity (RDI) of  80%.
Similar numbers of patients in both arms had RDIs of  80% for
oxaliplatin (75% and 80% of patients receiving cetuximab plus
Table 2. Efficacy Data in the ITT and KRAS Populations
Characteristic
ITT Population (n  337) KRAS Population (n  233) KRAS Wild Type (n  134) KRAS Mutant (n  99)
FOLFOX-4
(n  168)
Cetuximab 
FOLFOX-4
(n  169)
FOLFOX-4
(n  120)
Cetuximab 
FOLFOX-4
(n  113)
FOLFOX-4
(n  73)
Cetuximab 
FOLFOX-4
(n  61)
FOLFOX-4
(n  47)
Cetuximab 
FOLFOX-4
(n  52)
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
Best overall response
Complete response 1 0.6 2 1 3 3 2 2 1 1 2 3 2 4 0
Partial response 59 35 75 44 47 39 52 46 26 36 35 57 21 45 17 33
Stable disease 76 45 67 40 47 39 46 41 30 41 19 31 17 36 27 52
Progressive disease 21 13 18 11 17 14 10 9 12 16 3 5 5 11 7 13
Not assessable 11 7 7 4 6 5 3 3 4 5 2 3 2 4 1 2
Best overall response
rate†, %
All patients 36 46 42 48 37 61 49 33
95% CI 29-44 38-53 33-51 38-57 26-49 47-73 34-64 20-47
Odds ratio 1.516 1.312 2.544 0.507
95% CI 0.975-2.355 0.779-2.208 1.238-5.227 0.223-1.150
P (stratified CMH test) .064 .307 .011 .106
Disease control rate‡, % 81 85 81 89 78 92 85 85
95% CI 74-87 79-90 73-87 81-94 67-87 82-97 72-94 72-93
PFS time, months
Median 7.2 7.2 7.2 7.3 7.2 7.7 8.6 5.5
95% CI 6.0-7.8 5.6-7.7 6.0-7.9 5.6-8.1 5.6-7.4 7.1-12.0 6.5-9.5 4.0-7.4
Hazard ratio 0.931 0.928 0.570 1.830
95% CI 0.705-1.230 0.665-1.295 0.358-0.907 1.095-3.056
P (log-rank test) .6170 .6609 .0163 .0192
PFS rates, %
3 months 85 83 82 86 78 93 87 78
95% CI 79-90 78-89 75-89 80-93 69-88 87-100 77-97 67-90
6 months 59 53 60 54 54 66 69 39
95% CI 51-68 45-61 50-69 44-64 42-66 53-79 54-83 25-54
9 months 34 34 33 35 27 47 42 20
95% CI 26-43 26-43 23-43 25-45 15-39 33-62 24-61 7-33
12 months 12 24 13 20 13 30 14 6
95% CI 3-20 15-33 4-23 8-32 2-24 10-49 0-30 0-16
NOTE. P  0.05 for bold values.
Abbreviations: ITT, intention to treat; FOLFOX-4, oxaliplatin, leucovorin, and fluorouracil; CMH, Cochran-Mantel-Haenszel; PFS, progression-free survival.
As assessed by independent review. Best overall response on the ITT population was based on data available at the a priori fixed time of the confirmatory analysis.
†Complete response  partial response.
‡Complete response  partial response  stable disease.
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FOLFOX-4 and FOLFOX-4, respectively) and FU (67% and 70% of
patients, respectively). Reductions and delays in cetuximab dosing
were primarily because of skin reactions, and delays in chemotherapy
dosing were because of hematologic, GI, or neurologic reactions. In
the KRAS population, comparable levels of exposure were reached;
86% of patients who received cetuximab had a RDI 80%. RDIs of
 80% were also reported for 73% and 81% of patients receiving
oxaliplatin and for 65% and 72% of patients receiving FU in the
cetuximab plus FOLFOX-4 and FOLFOX-4 arms, respectively.
Efficacy
Efficacy data are summarized in Table 2. The best confirmed
overall response rate in the cetuximab plus FOLFOX-4 group was
46%, and in the FOLFOX-4 –alone group, this value was 36%. The
comparison between the two treatment groups resulted in a com-
mon ECOG PS–adjusted OR of 1.52 (95% CI, 0.98 to 2.36), indi-
cating an increase in the chance of a response in the cetuximab plus
FOLFOX-4 arm by 52%. This increase was not statistically signifi-
cant at the 5% level (ECOG PS–adjusted CMH test, P  .064). A
slightly greater treatment effect was observed in the group of par-
ticipants (n 153 v 152) with ECOG PS 0 to 1 (OR 1.65; 95% CI,
1.04 to 2.60; CMH test,P .032). Regarding the secondary efficacy
end points, although a marked benefit in relation to PFS time
was not detected (Table 2; Fig 2A), the addition of cetuximab to
FOLFOX-4 was associated with an approximate doubling of the R0
resection rate from 2.4% (four of 168 patients) for FOLFOX-4 alone
to 4.7% (eight of 169 patients) for cetuximab plus FOLFOX-4. The
median duration of response was also longer in the cetuximab group
(9.0 v 5.7 months).
KRAS mutations in codons 12/13 (hereinafter called KRAS
mutations) were detected in the tumor tissue of 99 of 233 (42%)
patients, 52 of whom received cetuximab plus FOLFOX-4 and 47
of whom received FOLFOX-4 alone (Table 2). No mutations were
detected in the tumors of 134 patients (58%; hereinafter called
KRAS wild-type tumors), 61 of whom received cetuximab plus
FOLFOX-4 and 73 of whom received FOLFOX-4 alone. In patients
whose tumors were scored as KRAS wild type, the addition of
cetuximab to FOLFOX-4 was associated with a 2.54-fold increased
chance for response compared with FOLFOX-4 alone (61% v 37%;
OR  2.54; 95% CI, 1.24 to 5.23; ECOG PS–adjusted CMH test,
P  .011). Conversely, for patients with tumor KRAS mutations,
the response rate for cetuximab plus FOLFOX-4 was lower, com-
pared with FOLFOX-4 alone (33% v 49%; OR 0.51; 95% CI, 0.22
to 1.15; ECOG PS–adjusted CMH test, P .106). The R0 resection
rate was more than doubled in patients with KRAS wild-type
tumors who received cetuximab plus FOLFOX-4 (six of 61 pa-
tients; 9.8%) compared with those who received FOLFOX-4 alone
(three of 73 patients; 4.1%). In contrast, in patients whose tumors
carried KRAS mutations, R0 resection rates were similar in both
treatment arms (one in 52 and one in 47 patients, respectively;
1.9% and 2.1%). However, due to the small patient numbers, these
data have to be interpreted with caution.
The risk of disease progression (Figs 2A and 2B) was similar for
both the ITT (cetuximab plus FOLFOX-4 v FOLFOX-4 alone; hazard
ratio [HR] 0.93; log-rank test,P .6170) and theKRASpopulation
(HR  0.93; log-rank test, P  .6609), adding additional evidence
consistent with the representability of the KRAS population. A
marked risk reduction for progression was evident between the study
arms when comparing patients according to whetherKRASmutations
were detected in their tumor DNA. Specifically, as summarized in
Table 2 and Figure 3, the addition of cetuximab to FOLFOX-4 was
associated with a 43% reduction in the risk of progression in patients
with KRAS wild-type tumors (Fig 3C; HR  0.57; log-rank test,
P .0163). In those patients receiving cetuximab plus FOLFOX-4, the
risk of disease progression was lower for those whose tumors were wild
type forKRAS, compared with those whose tumors carried mutations
(Fig 3A; HR 0.45; log-rank test, P .0009). However, in patients
whose tumors carried mutations ofKRAS, the risk of disease progres-
sion was found to be lower for those receiving FOLFOX-4 alone
compared with those receiving cetuximab plus FOLFOX-4 (Fig 3D;
A
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Fig 2. Kaplan and Meier plots for progression-free survival time for patients in each study arm in (A) the intention to treat (ITT) population and (B) the KRAS population.
Cet., cetuximab; FOLFOX-4, oxaliplatin, leucovorin, and fluorouracil; mo., months.
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HR  1.83; log-rank test, P  .0192). For patients receiving
FOLFOX-4 alone, a trend for reduced risk of disease progression
associated with tumor KRAS mutation was also apparent (Fig 3B;
HR 1.40; log-rank test, P .1655).
Safety
The most common AEs at any grade were skin and subcutaneous
tissue disorders (90%) and GI disorders (78%) in the cetuximab plus
FOLFOX-4 group, and GI disorders (73%) and myelotoxicity (71%)
in the FOLFOX-4–alone group. The most common grade 3/4 AEs
were neutropenia (30% v 34%), rash (11% v 0.6%), and diarrhea
(8% v 7%) respectively, for the cetuximab plus FOLFOX-4 versus the
FOLFOX-4– alone group (Table 3).
In the cetuximab plus FOLFOX-4 group, cetuximab was dis-
continued in 39 patients (23%), chemotherapy was discontinued
in 51 patients (30%), and both were discontinued in 16 patients
(9%) due to AEs. Chemotherapy was discontinued in 42 patients
(25%) in the FOLFOX-4 –alone group due to AEs. The most com-
mon reasons for cetuximab discontinuation were hypersensitivity
reactions (4%) and rash (4%), in accordance with guidelines pre-
specified in the protocol, and for chemotherapy discontinuation in
the cetuximab plus FOLFOX-4 group, neutropenia (4%) and neu-
ropathy (3%). In the FOLFOX-4–alone group, peripheral sensory
neuropathy (5%), neuropathy and paresthesia (4%), and neutropenia
(2%) were the most common reasons for treatment discontinuation.
At the time of analysis, 111 patients had died; 60 patients (35%)
in the cetuximab plus FOLFOX-4 group and 51 patients (30%) in the
FOLFOX-4–alone group, mainly due to PD (94 patients). No deaths
were related to cetuximab.
DISCUSSION
The rationale for testing cetuximab in combination with FOLFOX-4
rested on preclinical data suggesting that cetuximab improved the
antitumor activity of oxaliplatin and also on promising clinical
phase II study data.16,30 The confirmed best overall response rate
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Fig 3. Kaplan and Meier plots for progression-free survival time according to tumor KRAS mutation status in patients (pts) who received (A) cetuximab (Cet.) plus
oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) or (B) FOLFOX-4 alone and according to treatment arm for pts whose tumors were (C) wild type or (D) mutant for
KRAS. Progr., progression; Cens., censored; HR, hazard ratio.
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for the ITT population, as assessed by blinded independent review,
was increased by 10 percentage points by the addition of cetuximab
to FOLFOX-4, compared with FOLFOX-4 alone (46% v 36%).
Although this difference showed a clinically relevant and strong
trend, a statistically significant increase in the odds for a response
with the addition of cetuximab to FOLFOX-4 could not be estab-
lished (P .064).
Although there was no apparent difference in PFS time between
the ITT population treatment arms, when retrospective efficacy anal-
yses were carried out in the KRAS population according to KRAS
mutation status, striking differences were apparent in relation to tu-
mor response and the risk of disease progression. Patients whose
tumors were wild type for KRAS had a clinically relevant increase in
the chance of response (61% v 37%; OR  2.54; P  .011) and
decrease in the risk of disease progression (HR 0.57; P .016) in
the cetuximab plus FOLFOX-4 arm compared with those in the
FOLFOX-4 –alone arm. Somewhat unexpected was the observa-
tion that patients whose tumors carried a mutation in KRAS were
more likely to derive a clinical benefit if treated with FOLFOX-4
alone rather than cetuximab plus FOLFOX-4 (Fig 3D). Similarly,
considering patients receiving FOLFOX-4 alone, there was a trend
for improved progression-free survival time in patients whose
tumors carried a KRAS mutation (Fig 3B).
It remains to be seen whether the apparently better outcome
of patients whose tumors carried KRAS mutations who were
treated with FOLFOX-4 alone compared with those treated with
cetuximab plus FOLFOX-4 was a chance finding, or whether it
might have a biologic explanation. Given that a comparable effect
was not observed in equivalent patient groups in the CRYSTAL
study when cetuximab was added to FOLFIRI,23 the type of chem-
otherapy (platinum based compared with nonplatinum based)
may be a factor in any possible interaction. It is interesting to note
in this context that the subgroup of genotyped patients in the
randomized phase III CAIRO2 study whose tumors had a mutation
in the KRAS gene (n  196) who received capecitabine/oxaliplatin
plus bevacizumab (n 103) had significantly better PFS than those
who received the same regimen plus cetuximab (n 93).31
The OPUS and CAIRO2 studies therefore raise the possibility
that in relation to tumors with mutations in the KRAS gene, the
addition of EGFR-targeted agents to oxaliplatin-based chemotherapy
may impair the efficacy of a cytotoxic component of the combined
regimen. In addition, a specific interaction between bevacizumab and
cetuximab in relation to the treatment of tumors with KRAS muta-
tions cannot be excluded. Experimental studies are therefore war-
ranted to explore such hypothetical treatment effects inKRASmutant
mCRCs with a view to devising novel clinical strategies to allow exten-
sion of the benefit of anti-EGFR therapy to patients whose tumors
have KRAS mutations.
In line with recent findings from a phase I dose-escalation
study of cetuximab with FOLFIRI,32 and the first-line data from the
phase III CRYSTAL study,23 the results of the current analysis
confirm published data from previously treated mCRC, regarding
restriction of the activity of cetuximab to patients whose tumors
are wild type for KRAS.19-22,24 The KRAS data also emphasize the
fact that the higher clinical benefit associated with cetuximab es-
sentially may be masked, or at the least underestimated, when
considering overall populations of unselected patients in ran-
domized studies, as illustrated by the nonsignificant results in
response rate and the comparable risk of disease progression in
the ITT population.
The combination of cetuximab and FOLFOX-4 was generally
well tolerated, and there was no evidence to suggest that cetuximab
increased the frequency or severity of the known toxicities of oxalipla-
tin and FU or vice versa. In addition, the incidence and severity of skin
reactions, infusion-related reactions, and mucositis were consistent
with the known safety profile of cetuximab.
In conclusion, this study demonstrated that to a clinically
meaningful extent, the addition of cetuximab to FOLFOX-4 as
first-line treatment for mCRC increased the overall response rate
and reduced the risk of disease progression in patients whose
tumors were wild type forKRAS, compared with FOLFOX-4 alone.
These data confirm that KRAS mutation status is a powerful pre-
dictive factor in relation to the efficacy of cetuximab treatment, and
are a clear demonstration of the potential and increasing impor-
tance of tumor biomarker analysis as a component of treatment
selection in the clinic.
Table 3. Relevant Grade 3 or 4 Adverse Events Occurring in
 3% of Patients in Either Group
Grade 3/4 Adverse Event
FOLFOX-4
(n  168)
Cetuximab 
FOLFOX-4
(n  170)
No. of
Patients %
No. of
Patients %
Any grade 3/4 event 117 70 129 76
Neutropenia 57 34 51 30
Rash 1 0.6 19 11
Diarrhea 12 7 14 8
Leukopenia 10 6 12 7
Thrombocytopenia 4 2 7 4
Fatigue 5 3 7 4
Palmar-plantar erythrodysesthesia 1 0.6 7 4
Peripheral sensory neuropathy 12 7 7 4
Anemia 4 2 6 4
Composite categories
Skin reactions† 1 0.6 30 18
Infusion-related reactions‡ 3 2 8 5
Abbreviation: FOLFOX-4, oxaliplatin, leucovorin, and fluorouracil.
No grade 4 reactions.
†The special adverse event category skin reactions included the following
Medical Dictionary for Regulatory Activities 8.1 terms: acne, acne pustular,
cellulitis, dermatitis acneiform, dry skin, erysipelas, erythema, face edema,
folliculitis, growth of eyelashes, hair growth abnormal, hypertrichosis, nail bed
infection, nail bed inflammation, nail disorder, nail infection, paronychia,
pruritus, rash, rash erythematous, rash follicular, rash generalized, rash
macular, rash maculopapular, rash popular, rash pruritic, rash pustular, skin
exfoliation, skin hyperpigmentation, skin necrosis, staphylococcal scalded skin
syndrome, telangiectasia, wound necrosis, xerosis.
‡The special adverse event category infusion-related reactions included the
following Medical Dictionary for Regulatory Activities 8.1 terms: acute respi-
ratory failure, apnea, asthma, bronchial obstruction, bronchospasm, cyanosis,
dyspnea, dyspnea at rest, dyspnea exacerbated, dyspnea exertional, hypoxia,
orthopnea, respiratory distress, respiratory failure, chills, hyperpyrexia, pyr-
exia, acute myocardial infarction, angina pectoris, blood pressure decreased,
cardiac failure, cardiopulmonary failure, clonus, convulsion, epilepsy, hypoten-
sion, infusion related reaction, loss of consciousness, myocardial infarction,
myocardial ischemia, shock, sudden death and syncope, occurring on the first
day of treatment; and anaphylactic reaction, anaphylactic shock, anaphylactoid
reaction, anaphylactoid shock, drug hypersensitivity and hypersensitivity,
occurring at any time during treatment.
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